Clinical Trials Browser

Phase 1 × Congenital Abnormalities × Interleukin-2 × Clear all

NCT02316964 2020-03-09

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute